Study participants
ONCOLOGY, DISEASE PROGRESSION, DISEASE
A total of 19 patients were treated with EVER4010001 BID (3, 3, 6, and 7 patients dosed with 40, 60, 80, and 100 mg, respectively), of which 2 patients in the 100 mg EVER4010001 BID group were replaced and not included in determination of MTD. Most patients were male (57.9%), and all patients were of Asian‐Chinese origin and Han ethnicity (Table Demographics and baseline disease characteristicsAbbreviation: ECOG, Eastern Cooperative Oncology Group.At the time of data cut‐off (DCO) on August 17, 2021, 3 (15.8%) patients were still ongoing with study medication, 16 (84.2%) patients had discontinued. A total of 12 (63.2%) patients discontinued due to disease progression, 3 (15.8%) due to AEs, and 1 (5.3%) due to physician's decision (Table 